Conference Call 9/28/22 Scott Kelly, 22: 50: As

Quote:

---

Scott Kelly, 22: 50: As Dr. Arman mentioned, we do believe that leronlimab's role in HIV-NASH is a unique opportunity. We have the potential to assist with controlling the viral load, while possibly helping to reduce steatosis and fibrosis. NASH is a complex disease. But it is even more complex in the HIV population. People living with HIV may have multiple comorbidities. HIV virus may directly cause inflammation and fibrosis, while hepatotoxicity is associated with antiviral agent / aging and steatosis. In addition, HIV causes leakiness in the gut barrier, resulting in increased levels of endotoxin reaching the liver through the portal circulation. There is evidence that HIV itself may even bind with hepatocytes via the CCR5 receptor and trigger down stream cytokine responses that are both pro-inflammatory and pro-fibrotic in nature. And people living with HIV, the rate of NAFLD is approximately 50% and the the NASH rates are almost double the general population. Due to the underlying diagnosis of HIV, most of these patients are excluded from clinical trials for NASH, and this represents an unmet medical need.

24:00: So now I would like to introduce you to the newest members of our Scientific Advisory Board that Dr. Arman had mentioned. We are very proud of this. Dr. Stephan Gluk is the former vice president of global medical affairs at Celgene corporation since October 2014 until its acquisition by Bristol Meyer Squibb for $74 Million in 2019. He then served as the VP and the head of Oncology for Regeneron from 3/2020 - 3/2022 . Prior to Celgene, he was Professor at department of medicine at University of Miami in Florida. As VP of Global Medical Affairs at Celgene, he over saw breast, ovarian, bladder cancer activities worldwide, for the Celgene corporation as well as the Immunow Oncology program. He has been the principle investigator for 37 clinical studies in breast cancer. He has authored or co-authored over 250 articles. In addition, Dr. Gluk has written or cowritten a number of book chapters and numerous journal abstracts. He has presented more than 350 papers at national and international meetings. He will be assisting us in identifying partnership opportunities, trial designs, identifying collaborations, and solid tumor opportunities.

---